Imre study
This article was originally published in The Gray Sheet
Executive Summary
Published in the March issue of Cancer, the journal of the American Cancer Society, finds that 25 of 55 patients with chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome responded to treatment with the Imre Prosorba immunoadsorption column. Of the patients who responded, 61% had an "estimated one-year survival rate." Only 22% of patients who did not respond to the Prosorba therapy demonstrated a one-year survival rate. In the study, Harry Snyder, PhD, Imre Corporation, et al. find "protein A immunoadsorption...an effective and safe treatment for cancer chemotherapy-associated TTP/HUS".